###begin article-title 0
###xml 10 15 10 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD18</italic>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human RAD18 gene product interacts with HHR6A and HHR6B
###end article-title 0
###begin p 1
To whom correspondence should be addressed. Tel: +1 606 323 5784; Fax: +1 606 323 1059; Email: zwang@pop.uky.edu The authors wish it to be known that, in their opinion, the first three authors should be regarded as joint First Authors
###end p 1
###begin p 2
###xml 121 145 121 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Saccharomyces cerevisiae</italic>
###xml 531 536 531 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD18</italic>
###xml 1161 1166 1161 1166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD18</italic>
###xml 115 120 <span type="species:ncbi:4932">yeast</span>
###xml 121 145 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
###xml 344 349 <span type="species:ncbi:4932">yeast</span>
###xml 371 376 <span type="species:ncbi:9606">human</span>
###xml 389 394 <span type="species:ncbi:4932">yeast</span>
###xml 491 496 <span type="species:ncbi:9606">human</span>
###xml 508 513 <span type="species:ncbi:4932">yeast</span>
###xml 525 530 <span type="species:ncbi:9606">human</span>
###xml 729 734 <span type="species:ncbi:9606">Human</span>
###xml 823 828 <span type="species:ncbi:4932">yeast</span>
###xml 1084 1090 <span type="species:ncbi:9606">humans</span>
###xml 1209 1214 <span type="species:ncbi:9606">human</span>
During DNA replication, lesion bypass is an important cellular response to unrepaired damage in the genome. In the yeast Saccharomyces cerevisiae, Rad6 and Rad18 are required for both the error-free and error-prone lesion bypass mechanisms. Furthermore, Rad6-Rad18 interaction is thought to be critical at an early step during lesion bypass in yeast. Two closely related human homologs of yeast Rad6 have been identified as HHR6A and HHR6B. Here, we report a full-length cDNA coding for the human homolog of yeast Rad18. The human RAD18 gene codes for a protein of 484 amino acid residues with a calculated molecular weight of 54 804 Da, and the gene is localized to chromosome 3 between reference intervals D3S3591 and D3S1283. Human RAD18 protein (hRAD18) was found to interact with HHR6A and HHR6B. When co-expressed in yeast cells, stable hRAD18-HHR6A and hRAD18-HHR6B protein complexes were identified and purified to near homogeneity. Thus, through interaction and complex formation with HHR6A and HHR6B, RAD18 protein may play an important role in lesion bypass mech-anisms in humans. Consistent with its role as a fundamental lesion bypass protein, the RAD18 gene is ubiquitously expressed in various human tissues.
###end p 2
###begin p 3
DDBJ/EMBL/GenBank accession no. AF169796
###end p 3
###begin title 4
INTRODUCTION
###end title 4
###begin p 5
Many endogenous and exogenous agents frequently damage DNA. DNA lesions are subject to removal by DNA repair pathways. However, DNA repair often cannot remove all lesions from the genome due to limited cellular repair capacity, inefficiently repaired regions of the genome or poorly recognized damage. During DNA replication, unrepaired DNA lesions could pose a serious problem for the replication machinery, since many lesions block the replication polymerases. In response, cells have evolved a sophisticated system called lesion bypass to overcome such replication blockage.
###end p 5
###begin p 6
###xml 13 37 13 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Saccharomyces cerevisiae</italic>
###xml 130 134 130 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD6</italic>
###xml 139 144 139 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD18</italic>
###xml 152 153 152 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c1">1</xref>
###xml 154 155 154 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c2">2</xref>
###xml 198 199 198 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c3">3</xref>
###xml 236 237 236 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c4">4</xref>
###xml 238 239 238 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c6">6</xref>
###xml 316 317 316 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c4">4</xref>
###xml 318 319 318 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c6">6</xref>
###xml 515 516 515 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c4">4</xref>
###xml 794 795 794 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c5">5</xref>
###xml 7 12 <span type="species:ncbi:4932">yeast</span>
###xml 13 37 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
In the yeast Saccharomyces cerevisiae, lesion bypass consists of error-free and error-prone mechanisms, both of which require the RAD6 and RAD18 genes (1,2). Rad6 is a ubiquitin-conjugating enzyme (3) and it forms a complex with Rad18 (4-6). Rad18 is a zinc finger protein with single-stranded DNA binding activity (4-6). It has been proposed that Rad18 may act to load Rad6 onto sites of DNA damage where its ubiquitin-conjugating activity could subsequently modify the stalled replicative DNA polymerase complex (4). This model postulates that Rad6 and Rad18 act at an early step of lesion bypass and their interaction is critical for subsequent processes to bypass a lesion. Supporting this hypothesis, the Rad6-Rad18 interaction is indispensable for the function of Rad18 in UV resistance (5).
###end p 6
###begin p 7
###xml 154 158 154 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD6</italic>
###xml 160 165 160 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD18</italic>
###xml 167 171 167 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">REV1</italic>
###xml 173 177 173 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">REV3</italic>
###xml 179 183 179 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">REV6</italic>
###xml 185 189 185 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">REV7</italic>
###xml 194 198 194 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NGM2</italic>
###xml 200 201 200 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c7">7</xref>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c13">13</xref>
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c14">14</xref>
###xml 499 501 496 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c15">15</xref>
###xml 551 553 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c15">15</xref>
###xml 556 560 553 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">REV6</italic>
###xml 565 569 562 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NGM2</italic>
The damage-induced mutagenesis pathway is a major mechanism of error-prone lesion bypass. This mutagenesis pathway requires at least the following genes: RAD6, RAD18, REV1, REV3, REV6, REV7 and NGM2 (7-13). Rev1 is a dCMP transferase capable of inserting a dCMP opposite a template apurinic/apyrimidinic (AP) site (14) and it likely plays an additional role in error-prone lesion bypass (D.K.Rajpal, X.Wu and Z.Wang, submitted for publication). Rev3 is the catalytic subunit of DNA polymerase zeta (15) and Rev7 is a small subunit of this polymerase (15). REV6 and NGM2 have not yet been cloned.
###end p 7
###begin p 8
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c16">16</xref>
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c17">17</xref>
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c18">18</xref>
###xml 308 310 308 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c16">16</xref>
###xml 366 368 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c19">19</xref>
###xml 451 453 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c19">19</xref>
###xml 747 749 745 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c20">20</xref>
###xml 27 32 <span type="species:ncbi:4932">yeast</span>
###xml 598 603 <span type="species:ncbi:4932">yeast</span>
It has been suggested that yeast error-free lesion bypass is composed of two mechanisms: the Rad5 mechanism (16) and the Rad30 mechanism (17,18). Very little is known about the Rad5 error-free mechanism. Rad5 is a member of the DNA helicase family, and its ATPase activity has been experimentally confirmed (16). Rad30 was recently identified as DNA polymerase eta (19). It is capable of error-free translesion synthesis opposite a template TT dimer (19). Thus, Rad30 functions as an error-free lesion bypass mechanism in response to UV radiation. However, recent biochemical studies with purified yeast Rad30 suggest that this polymerase could also function as an error-prone mechanism in response to certain DNA lesions such as AP sites in DNA (20).
###end p 8
###begin p 9
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c21">21</xref>
###xml 170 174 170 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">REV1</italic>
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c22">22</xref>
###xml 181 185 181 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">REV3</italic>
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c23">23</xref>
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c24">24</xref>
###xml 198 202 198 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">REV7</italic>
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c25">25</xref>
###xml 465 467 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c26">26</xref>
###xml 468 470 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c27">27</xref>
###xml 834 839 834 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD18</italic>
###xml 42 48 <span type="species:ncbi:9606">humans</span>
###xml 82 87 <span type="species:ncbi:4932">yeast</span>
###xml 117 123 <span type="species:ncbi:9606">humans</span>
###xml 164 169 <span type="species:ncbi:9606">human</span>
###xml 296 301 <span type="species:ncbi:4932">yeast</span>
###xml 329 335 <span type="species:ncbi:9606">humans</span>
###xml 355 360 <span type="species:ncbi:9606">human</span>
###xml 376 381 <span type="species:ncbi:4932">yeast</span>
###xml 571 576 <span type="species:ncbi:4932">yeast</span>
###xml 580 586 <span type="species:ncbi:9606">humans</span>
###xml 726 731 <span type="species:ncbi:4932">yeast</span>
###xml 750 756 <span type="species:ncbi:9606">humans</span>
###xml 828 833 <span type="species:ncbi:9606">human</span>
###xml 951 956 <span type="species:ncbi:9606">human</span>
Much less is known about lesion bypass in humans. Two closely related homologs of yeast Rad6 have been identified in humans as HHR6A and HHR6B (21). More recently, human REV1 (22), REV3 (23,24) and REV7 (25) genes have been isolated. Thus, a damage-induced mutagenesis pathway similar to that in yeast is probably operational in humans. Additionally, the human counterpart of yeast Rad30 has been identified as the XPV (xeroderma pigmentosum variant) gene product (26,27). These observations strongly suggest that a lesion bypass system may have been well conserved from yeast to humans in response to unrepaired DNA damage during replication. Since Rad18 is indispensable for both error-free and error-prone lesion bypass in yeast, we asked whether humans possess a counterpart to this protein. In this report, we describe the human RAD18 gene, its chromosomal localization and its ubiquitous expression in various tissues. Furthermore, we show that human RAD18 protein interacts and forms stable complexes with HHR6A and HHR6B.
###end p 9
###begin title 10
MATERIALS AND METHODS
###end title 10
###begin title 11
Materials
###end title 11
###begin p 12
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c28">28</xref>
###xml 299 346 299 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">leu2,3-112 trp1-289 ura3-52 his7-2 lys1-1 rad18</italic>
###xml 348 352 348 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Leu2</italic>
###xml 413 415 413 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c29">29</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 207 212 <span type="species:ncbi:4932">Yeast</span>
###xml 248 253 <span type="species:ncbi:9606">human</span>
###xml 359 364 <span type="species:ncbi:4932">yeast</span>
###xml 476 481 <span type="species:ncbi:10090">mouse</span>
###xml 524 527 <span type="species:ncbi:10116">rat</span>
###xml 743 746 <span type="species:ncbi:10116">rat</span>
###xml 826 831 <span type="species:ncbi:10090">mouse</span>
Human EST clones EST182472 (GenBank accession no. AA311754), yd06a07.r1 (GenBank accession no. T80555) and nm33a08.s1 (GenBank accession no. AA572955) were purchased from Research Genetics (Huntsville, AL). Yeast strains used for the expression of human proteins were W303-1B (28) and FF18739 (MATa leu2,3-112 trp1-289 ura3-52 his7-2 lys1-1 rad18::Leu2). The yeast strain used for the two-hybrid assays was Y190 (29). Protease inhibitors, alkaline phosphatase-conjugated anti-mouse IgG, alkaline phosphatase-conjugated anti-rat IgG, 5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium were obtained from Sigma (St Louis, MO). Protein G-agarose beads and restriction endonucleases were purchased from Gibco BRL (Gaithersburg, MD). A rat monoclonal anti-HA antibody was from Boehringer Mannheim (Indianapolis, IN). A mouse monoclonal anti-His antibody was from Qiagen (Valencia, CA).
###end p 12
###begin title 13
Protease inhibitors
###end title 13
###begin p 14
###xml 425 426 411 412 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 436 437 422 423 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
The final concentrations of protease inhibitors used were 1 mM PMSF, 300 microg/ml benzamidine and 1 microg/ml each of antipain, chymostatin, leupeptin and pepstatin. These protease inhibitors were prepared as a 100x mixture in ethanol and stored at -20degreesC. Benzamidine and PMSF were weighed and dissolved directly in ethanol. Antipain, chymostatin, leupeptin and pepstatin were prepared as 10 mg/ml stock solutions in H2O, DMSO, H2O and methanol, respectively. When needed, protease inhibitors were added to buffers just before use.
###end p 14
###begin title 15
Plasmid constructions
###end title 15
###begin p 16
###xml 32 37 32 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD18</italic>
###xml 116 119 116 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pfu</italic>
###xml 284 289 284 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD18</italic>
###xml 312 315 312 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bam</italic>
###xml 322 325 322 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xba</italic>
###xml 616 621 616 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD18</italic>
###xml 667 670 667 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nco</italic>
###xml 719 722 719 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nco</italic>
###xml 777 779 777 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c29">29</xref>
###xml 26 31 <span type="species:ncbi:9606">human</span>
###xml 52 57 <span type="species:ncbi:4932">yeast</span>
###xml 63 68 <span type="species:ncbi:9606">human</span>
###xml 278 283 <span type="species:ncbi:9606">human</span>
###xml 400 405 <span type="species:ncbi:4932">yeast</span>
###xml 494 499 <span type="species:ncbi:9606">human</span>
###xml 581 586 <span type="species:ncbi:4932">yeast</span>
###xml 610 615 <span type="species:ncbi:9606">human</span>
###xml 736 741 <span type="species:ncbi:4932">yeast</span>
To construct plasmids for human RAD18 expression in yeast, the human cDNA clone EST182472 was amplified by PCR with Pfu DNA polymerase (Stratagene, La Jolla, CA) using the primers 5'-CGCGGATCCTCCATGGACTCCCTGGCC-3' and 5'-GCTCATGACCATGGAAGAGAAGGAGAATGGC-3'. The resulting 1.9 kb human RAD18 cDNA was cleaved with BamHI and XbaI restriction endonucleases and cloned into the corresponding sites of the yeast expression vector pEGLha, generating pEGLha-hRAD18. Expression of pEGLha-hRAD18 yielded human RAD18 protein containing the HA tag at its N-terminus. To construct plasmids for yeast two-hybrid assays, the human RAD18 cDNA was removed from the EST182472 clone by NcoI restriction digestion and then cloned into the NcoI site of the yeast two-hybrid vectors pAS2 and pACT2 (29), generating pAS2-hRAD18 and pACT2-hRAD18, respectively.
###end p 16
###begin p 17
###xml 111 114 111 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pfu</italic>
###xml 254 259 254 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HHR6A</italic>
###xml 282 285 282 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hin</italic>
###xml 294 297 294 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bgl</italic>
###xml 346 349 346 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hin</italic>
###xml 526 531 526 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HHR6A</italic>
###xml 584 589 584 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HHR6A</italic>
###xml 620 623 620 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bgl</italic>
###xml 630 633 630 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nco</italic>
###xml 681 684 681 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bam</italic>
###xml 691 694 691 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nco</italic>
###xml 750 752 750 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c29">29</xref>
###xml 821 826 821 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HHR6B</italic>
###xml 922 925 922 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pfu</italic>
###xml 1072 1077 1072 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HHR6B</italic>
###xml 1100 1103 1100 1103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nco</italic>
###xml 1109 1112 1109 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bgl</italic>
###xml 1161 1164 1161 1164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bam</italic>
###xml 1171 1174 1171 1174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nco</italic>
###xml 1230 1232 1230 1232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c29">29</xref>
###xml 47 52 <span type="species:ncbi:4932">yeast</span>
###xml 58 63 <span type="species:ncbi:9606">human</span>
###xml 248 253 <span type="species:ncbi:9606">human</span>
###xml 377 382 <span type="species:ncbi:4932">yeast</span>
###xml 482 487 <span type="species:ncbi:9606">human</span>
###xml 545 550 <span type="species:ncbi:4932">yeast</span>
###xml 709 714 <span type="species:ncbi:4932">yeast</span>
###xml 840 845 <span type="species:ncbi:4932">yeast</span>
###xml 869 874 <span type="species:ncbi:9606">human</span>
###xml 1066 1071 <span type="species:ncbi:9606">human</span>
###xml 1189 1194 <span type="species:ncbi:4932">yeast</span>
To construct a plasmid for HHR6A expression in yeast, the human EST clone yd06a07.r1 was amplified by PCR with Pfu DNA polymerase using the primers 5'-GAAGATCTCCCATGGACATGTCCACCCCGGCTC-3' and 5'-GAAGATCTAA-GCTTCTTTAAACTGTACCCGGGG-3'. The resulting human HHR6A cDNA was cleaved with HindIII and BglII restriction endonucleases and cloned into the HindIII and BamHI sites of the yeast expression vector pEGUh6, generating pEGUh6-HHR6A. Expression of this plasmid yielded 6xHis-tagged human HHR6A at its N-terminus. To construct HHR6A plasmids for yeast two-hybrid assays, the amplified HHR6A DNA fragment was cleaved with BglII and NcoI restriction endonucleases and cloned into the BamHI and NcoI sites of the yeast two-hybrid vectors pAS2 and pACT2 (29), generating pAS2-HHR6A and pACT2-HHR6A, respectively. To construct HHR6B plasmids for yeast two-hybrid assays, the human EST clone nm33a08.s1 was amplified by PCR with Pfu DNA polymerase using the primers 5'-CATGCCATGG-GATCCATGCATGTCGACCCCGGCC-3' and 5'-GAAGAT-CTAAGCTTTGCAGAATCCTTAAAACCTGTGGC-3'. The resulting human HHR6B cDNA was cleaved with NcoI and BglII restriction endonucleases and cloned into the BamHI and NcoI sites of the yeast two-hybrid vectors pAS2 and pACT2 (29), generating pAS2-HHR6B and pACT2-HHR6B, respectively.
###end p 17
###begin title 18
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD18</italic>
###xml 38 43 <span type="species:ncbi:9606">human</span>
Detection of RAD18 gene expression in human tissues
###end title 18
###begin p 19
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD18</italic>
###xml 225 226 225 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 497 502 497 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD18</italic>
###xml 591 592 587 588 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 679 682 671 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
###xml 40 45 <span type="species:ncbi:9606">human</span>
###xml 78 83 <span type="species:ncbi:9606">Human</span>
###xml 253 258 <span type="species:ncbi:9606">human</span>
###xml 491 496 <span type="species:ncbi:9606">human</span>
Expression of the RAD18 gene in various human tissues was detected by RT-PCR. Human multiple tissue cDNA panels were purchased from Clontech Laboratories (Palo Alto, CA) and used for PCR. These cDNAs were derived from poly(A)+ mRNA samples from various human tissues with reverse trans-criptase and normalized against glyceraldehyde-3-phospate dehydrogenase cDNA by the manufacturer. Two PCR primers, CCACTCTCGACATCCACTTTG and CCTTTTCTGTTTG-GTCCTTTG, were used to amplify a 433 bp region of human RAD18 cDNA. PCR reactions (20 microl) contained 0.4 ng cDNA, 5 pmol each of primers, 2 mM MgCl2, 20 mM Tris-HCl, pH 8.0, 50 mM KCl, 200 microM each dATP, dCTP, dGTP and dTTP and 1 U Taq DNA polymerase. After heating at 94degreesC for 30 s, 35 cycles of amplification were performed according to the following conditions: 20 s denaturation at 94degreesC, 30 s annealing at 55degreesC and 45 s extension at 68degreesC. Reaction products were separated by electrophoresis on a 1% agarose gel containing 0.5 microg/ml ethidium bromide.
###end p 19
###begin title 20
###xml 0 5 <span type="species:ncbi:4932">Yeast</span>
Yeast two-hybrid assays for protein interactions
###end title 20
###begin p 21
###xml 629 630 623 624 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 633 634 627 628 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 645 646 639 640 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 648 649 642 643 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 674 675 668 669 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 0 5 <span type="species:ncbi:4932">Yeast</span>
Yeast Y190 cells were transformed with plasmids pAS2-hRAD18, pAS2-HHR6A, pAS2-HHR6B, pACT2-hRAD18, pACT2-HHR6A and pACT2-HHR6B, individually or in combination: pAS2-hRAD18 + pACT2-HHR6A, pAS2-hRAD18 + pACT2-HHR6B, pAS2-HHR6A + pACT2-hRAD18 and pAS2-HHR6B + pACT2-hRAD18. Transformed cells were grown on minimum plates for 4-6 days at 30degreesC. Colonies from each plate were transferred to a nitrocellulose filter and permeablized by freezing the filters in liquid nitrogen for 10 s followed by thawing at room temperature. The filters with the colony side up were placed on Whatman no. 1 paper presoaked with Z buffer (60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCl and 1 mM MgSO4) containing 38.6 mM beta-mercapto-ethanol and 0.5 mg/ml X-Gal. Following incubation at 30degreesC, cellular beta-galactosidase activity was detected by the appearance of blue color in colonies derived from the colorless X-Gal.
###end p 21
###begin title 22
Co-immunoprecipitation
###end title 22
###begin p 23
###xml 566 568 554 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c30">30</xref>
###xml 679 680 667 668 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 0 5 <span type="species:ncbi:4932">Yeast</span>
###xml 241 246 <span type="species:ncbi:9606">human</span>
###xml 336 341 <span type="species:ncbi:4932">yeast</span>
Yeast cells containing pEGLha-hRAD18, pEGUh6-HHR6A or pEGUh6-HHR6B individually or pEGLha-hRAD18 + pEGUh6-HHR6A or pEGLha-hRAD18 + pEGUh6-HHR6B were grown in minimum medium containing 2% sucrose at 30degreesC for 1.5 days. Expression of the human proteins was induced by diluting the culture 10-fold in YPG medium (2% Bacto-peptone, 1% yeast extract and 2% galactose) supplemented with 0.5% sucrose and growing at 30degreesC for 12 h. Cells were collected by centrifugation and then homogenized with Zirconium beads in a Bead-beater essentially as described before (30) in HNT buffer containing 20 mM HEPES, pH 7.9, 0.1% Triton X-100, 50 mM NaCl, 5 mM EDTA, 10 mM DTT, 10 mM MgSO4 and protease inhibitors. Cell-free extracts were obtained following centrifugation to remove cell debris.
###end p 23
###begin p 24
###xml 785 787 762 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c31">31</xref>
###xml 910 912 887 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c31">31</xref>
###xml 120 123 <span type="species:ncbi:10116">rat</span>
###xml 293 298 <span type="species:ncbi:9606">human</span>
###xml 835 840 <span type="species:ncbi:9606">human</span>
###xml 993 998 <span type="species:ncbi:10090">mouse</span>
###xml 1094 1099 <span type="species:ncbi:10090">mouse</span>
###xml 1116 1121 <span type="species:ncbi:9606">human</span>
###xml 1380 1385 <span type="species:ncbi:9606">human</span>
###xml 1444 1447 <span type="species:ncbi:10116">rat</span>
Protein G-agarose beads (10 microl) were washed with 1 ml of HNT buffer three times and then incubated with 200 ng of a rat monoclonal anti-HA antibody at 4degreesC for 3 h. After washing with 1 ml of HNT buffer four times to remove free antibody, cell-free extracts (1-1.5 mg) containing the human proteins were added to the protein G-antibody complex and incubated at 4degreesC for 3 h. Proteins bound to the protein G-agarose-anti-HA antibody complex were collected by centrifugation and washed thoroughly with 300 microl HNT buffer six to eight times. Immuno-precipitated proteins were resuspended in buffer (25 mM Tris-HCl, pH 6.8, 0.05% SDS, 71.5 mM beta-mercapto-ethanol, 5% glycerol and 0.02% bromophenol blue) and separated by electrophoresis on a 15% SDS-polyacrylamide gel (31). After transfer to a nitrocellulose membrane, human RAD18, HHR6A and HHR6B proteins were identified by western blotting (31) using two sequential detection steps. First, the membrane was incubated with a mouse monoclonal anti-His antibody, followed by incubation with alkaline phosphatase-conjugated anti-mouse IgG. His-tagged human HHR6A or HHR6B was visualized after color development by incubating the membrane with 5-bromo-4-chloro-3-indolyl phosphate (0.3 mM) and nitroblue tetrazolium (0.4 mM) in buffer containing 5 mM Tris-HCl, pH 7.5, 17 mM NaCl and 0.05% Tween 20. Then, HA-tagged human RAD18 was detected by incubating the same membrane with a rat monoclonal anti-HA antibody, followed by secondary antibody incubation and color development as before.
###end p 24
###begin title 25
Purification of hRAD18-HHR6A and hRAD18-HHR6B protein complexes
###end title 25
###begin p 26
###xml 731 732 710 711 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 0 5 <span type="species:ncbi:4932">Yeast</span>
###xml 168 173 <span type="species:ncbi:9606">human</span>
###xml 1221 1226 <span type="species:ncbi:10090">mouse</span>
###xml 1271 1276 <span type="species:ncbi:9606">human</span>
###xml 1324 1327 <span type="species:ncbi:10116">rat</span>
Yeast cells harboring pEGLha-hRAD18 and pEGUh6-HHR6A or pEGLha-hRAD18 and pEGUh6-HHR6B were grown in minimum medium containing 2% sucrose for 2 days. Expression of the human proteins was induced by diluting the culture 10-fold in 16 l of YPG medium supplemented with 0.5% sucrose and growing for 15 h at 30degreesC. Cells were collected by centrifugation and washed with water. After resuspending in an extraction buffer containing 50 mM Tris-HCl, pH 7.5, 600 mM KCl, 10% sucrose, 5 mM beta-mercaptoethanol and protease inhibitors, cells were homogenized on ice with Zirconium beads in a Bead-beater for 15 pulses of 30 s each. The clarified extract (approximately100 ml) was loaded onto a HiTrap chelating column charged with NiSO4 (2 x 5 ml; Amersham Pharmacia Biotech, Piscataway, NJ). The column was washed with 240 ml of Ni buffer A (50 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 10% glycerol, 5 mM beta-mercaptoethanol and protease inhibitors) containing 10 mM imidazole, followed by a wash with 240 ml of Ni buffer A containing 35 mM imidazole. Bound proteins were eluted with a linear gradient (300 ml) of 35-250 mM imidazole in Ni buffer A. The His-tagged HHR6A or HHR6B protein was identified by western blotting using a mouse monoclonal anti-His antibody. The HA-tagged human RAD18 was detected by western blotting using a rat monoclonal anti-HA antibody. The pooled sample was concentrated with PEG 10,000 and desalted through 5 x 5 ml Sephadex G-25 columns in buffer A (50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 10% glycerol, 5 mM beta-mercaptoethanol and protease inhibitors) containing 50 mM KCl.
###end p 26
###begin p 27
###xml 691 693 655 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c31">31</xref>
For further purification of the hRAD18-HHR6B complex, the desalted Ni column sample (approximately20 ml) was loaded onto a FPLC Mono S HR5/5 column. After washing the column with 10 ml of buffer A, bound proteins were eluted with a 30 ml linear gradient of 50-400 mM KCl in buffer A. The hRAD18-HHR6B protein complex eluted at approximately140 mM KCl. The Mono S sample was desalted as before and loaded onto a FPLC Mono Q HR5/5 column. After washing the column with 10 ml of buffer A, bound proteins were eluted with a 30 ml linear gradient of 50-500 mM KCl in buffer A. The hRAD18-HHR6B protein complex was eluted at approximately350 mM KCl. In addition to western blots, silver staining (31) of SDS-polyacrylamide gels was also used to visualize proteins during purification. The Silver Stain Plus kit from Bio-Rad (Hercules, CA) was used according to the manufacturer's recommended conditions.
###end p 27
###begin p 28
For further purification of the hRAD18-HHR6A complex, the desalted Ni column sample (approximately20 ml) was loaded onto a FPLC Mono Q HR5/5 column and eluted as described above. Fractions containing the hRAD18-HHR6A complex (3 ml) were concentrated with PEG 10,000 to 250 microl and loaded onto a FPLC Superdex 200 HR 10/30 gel filtration column (Amersham Pharmacia Biotech) that had been equilibrated in buffer A containing 150 mM KCl. The hRAD18-HHR6A complex was then eluted in the same buffer.
###end p 28
###begin title 29
RESULTS
###end title 29
###begin title 30
###xml 6 11 6 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD18</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human RAD18 gene
###end title 30
###begin p 31
###xml 610 612 610 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c32">32</xref>
###xml 869 870 869 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 870 871 870 871 <sub xmlns:xlink="http://www.w3.org/1999/xlink">N</sub>
###xml 879 882 879 882 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;13</sup>
###xml 1040 1045 1040 1045 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD18</italic>
###xml 10 15 <span type="species:ncbi:4932">yeast</span>
###xml 99 104 <span type="species:ncbi:9606">human</span>
###xml 116 121 <span type="species:ncbi:9606">human</span>
###xml 678 683 <span type="species:ncbi:9606">human</span>
###xml 841 846 <span type="species:ncbi:4932">yeast</span>
###xml 937 942 <span type="species:ncbi:9606">human</span>
###xml 958 963 <span type="species:ncbi:4932">yeast</span>
###xml 1034 1039 <span type="species:ncbi:9606">human</span>
Using the yeast Rad18 protein sequence, we searched the non-redundant GenBank CDS database for its human homolog. A human EST sequence (GenBank accession no. AA311754) was identified. We then determined the entire nucleotide sequence of this clone. It contains an open reading frame of 1455 bp, a 70 bp 5' non-coding region and a 1524 bp 3' non-coding region. An in-frame stop codon lies 24 bp upstream of the putative ATG start codon. The sequence context of this ATG (CGACCATGG) matches well with the Kozak consensus sequence (CCACCATGG) that is commonly found surrounding the mammalian ATG initiator codon (32). Therefore, this clone contains a full-length cDNA coding for a human protein of 484 amino acid residues with a calculated molecular weight of 54 804 Da. Upon searching GenBank with the putative protein sequence, we identified yeast Rad18 as its homolog (PN = 1 x e-13). Hence, we conclude that this cDNA clone codes for a human homolog of the yeast lesion bypass protein Rad18. Accordingly, this gene is referred to as human RAD18 (GenBank accession no. AF169796).
###end p 31
###begin p 32
###xml 142 143 142 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd425f1">1</xref>
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c33">33</xref>
###xml 430 431 430 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd425f1">1</xref>
###xml 41 46 <span type="species:ncbi:9606">human</span>
###xml 51 56 <span type="species:ncbi:4932">yeast</span>
###xml 190 195 <span type="species:ncbi:4932">yeast</span>
###xml 226 231 <span type="species:ncbi:9606">human</span>
Comparison of the RAD18 proteins between human and yeast showed significant sequence conservation, with 26% identity and 59% similarity (Fig. 1). Furthermore, several structural features of yeast Rad18 are also present in the human protein, including an N-terminal C3HC4 zinc finger motif, also known as the RING finger motif (33), a C2HC zinc finger motif, a basic region near the C-terminus and a C-terminal acidic region (Fig. 1).
###end p 32
###begin title 33
###xml 38 43 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD18</italic>
###xml 32 37 <span type="species:ncbi:9606">human</span>
Chromosomal localization of the human RAD18 gene
###end title 33
###begin p 34
###xml 78 83 78 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD18</italic>
###xml 468 473 468 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD18</italic>
###xml 72 77 <span type="species:ncbi:9606">human</span>
###xml 115 120 <span type="species:ncbi:9606">human</span>
###xml 462 467 <span type="species:ncbi:9606">human</span>
We searched the non-redundant database of GenBank STS division with the human RAD18 cDNA sequence and identified a human STS (WI-13593). The location of this STS was assigned to 55.8 cR from the top of the chromosome 3 linkage group by Radiation Hybrid Mapping (Whitehead Institute/MIT Center for Genome Research, Cambridge, MA). On GeneMap'98 it was mapped to a physical position between reference intervals D3S3591 and D3S1283. Therefore, we conclude that the human RAD18 gene is located on chromosome 3 between D3S3591 and D3S1283.
###end p 34
###begin title 35
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD18</italic>
###xml 40 45 <span type="species:ncbi:9606">human</span>
Expression of the RAD18 gene in various human tissues
###end title 35
###begin p 36
###xml 54 56 54 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c22">22</xref>
###xml 57 59 57 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c24">24</xref>
###xml 60 62 60 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c26">26</xref>
###xml 63 65 63 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c27">27</xref>
###xml 192 197 192 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD18</italic>
###xml 304 305 304 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd425f2">2</xref>
###xml 307 312 307 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD18</italic>
###xml 420 425 420 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD18</italic>
###xml 46 52 <span type="species:ncbi:9606">humans</span>
###xml 129 134 <span type="species:ncbi:9606">human</span>
###xml 186 191 <span type="species:ncbi:9606">human</span>
###xml 270 275 <span type="species:ncbi:9606">human</span>
###xml 364 369 <span type="species:ncbi:9606">human</span>
###xml 460 466 <span type="species:ncbi:9606">humans</span>
Apparently, lesion bypass mechanisms exist in humans (22-24,26,27). However, it is not known whether hRAD18 functions in various human tissues. As an indication of the importance of the human RAD18 gene in response to DNA damage, we examined its expression in different human tissues. As shown in Figure 2, RAD18 expression was detected by RT-PCR in all of the 16 human tissues examined. Therefore, we conclude that the RAD18 gene is ubiquitously expressed in humans.
###end p 36
###begin title 37
###xml 15 20 <span type="species:ncbi:9606">human</span>
Interaction of human RAD18 protein with HHR6A and HHR6B
###end title 37
###begin p 38
###xml 43 44 43 44 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c4">4</xref>
###xml 45 46 45 46 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c6">6</xref>
###xml 225 230 225 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD18</italic>
###xml 232 238 232 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hRAD18</italic>
###xml 934 936 931 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c29">29</xref>
###xml 958 959 955 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd425f3">3</xref>
###xml 1352 1353 1340 1341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd425f3">3</xref>
###xml 13 18 <span type="species:ncbi:4932">yeast</span>
###xml 66 71 <span type="species:ncbi:9606">human</span>
###xml 105 110 <span type="species:ncbi:9606">human</span>
###xml 195 200 <span type="species:ncbi:4932">yeast</span>
###xml 219 224 <span type="species:ncbi:9606">Human</span>
###xml 427 432 <span type="species:ncbi:4932">yeast</span>
###xml 653 658 <span type="species:ncbi:9606">human</span>
###xml 872 877 <span type="species:ncbi:4932">yeast</span>
###xml 968 973 <span type="species:ncbi:4932">yeast</span>
###xml 1224 1229 <span type="species:ncbi:4932">yeast</span>
Based on the yeast Rad6-Rad18 interaction (4-6), we asked whether human RAD18 protein interacts with the human Rad6 counterparts, HHR6A and HHR6B. This question was initially addressed using the yeast two-hybrid assay. Human RAD18 (hRAD18) was cloned into the vector pAS2, yielding pAS2-hRAD18. HHR6A and HHR6B were cloned into the vector pACT2, yielding pACT2-HHR6A and pACT2-HHR6B, respectively. Expression of pAS2-hRAD18 in yeast cells produced a RAD18 fusion protein containing the Gal4 DNA binding domain. Expression of pACT2-HHR6A and pACT2-HHR6B produced the respective fusion proteins containing the Gal4 activation domain. Interactions between human RAD18 and HHR6A or HHR6B would physically bring the Gal4 DNA binding and activation domains close together to activate Gal4-dependent promoters. One Gal4 target is the beta-galactosidase gene, whose activation in yeast is indicated by blue colonies in the presence of X-Gal (29). As shown in Figure 3G and H, yeast cells containing both pAS2-hRAD18 and pACT2-HHR6A or both pAS2-hRAD18 and pACT2-HHR6B activated the beta-galactosidase gene as evidenced by the appearance of blue colonies following beta-galactosidase filter lift assays. In control experiments using yeast cells transformed with pAS2-hRAD18, pACT2-HHR6A or pACT2-HHR6B alone, the beta-galactosidase gene was not activated (Fig. 3A-C).
###end p 38
###begin p 39
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD18</italic>
###xml 258 259 255 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd425f3">3</xref>
###xml 408 409 402 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd425f3">3</xref>
###xml 16 21 <span type="species:ncbi:9606">human</span>
###xml 240 245 <span type="species:ncbi:4932">yeast</span>
###xml 446 451 <span type="species:ncbi:9606">human</span>
Similarly, when human RAD18 was cloned into the pACT2 vector (pACT2-hRAD18) and HHR6A or HHR6B were cloned into the pAS2 vector (pAS2-HHR6A and pAS2-HHR6B, respectively), these plasmids alone did not activate the beta-galactosidase gene in yeast cells (Fig. 3D-F). In contrast, plasmids pACT2-hRAD18 and pAS2-HHR6A together or pACT2-hRAD18 and pAS2-HHR6B together activated the beta-galactosidase gene (Fig. 3I and J). These results suggest that human RAD18 protein interacts with both HHR6A and HHR6B.
###end p 39
###begin p 40
###xml 447 448 447 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd425f4">4</xref>
###xml 550 558 550 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 599 600 599 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd425f4">4</xref>
###xml 817 818 817 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd425f4">4</xref>
###xml 953 954 953 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd425f4">4</xref>
###xml 120 125 <span type="species:ncbi:9606">human</span>
###xml 222 227 <span type="species:ncbi:4932">yeast</span>
###xml 265 270 <span type="species:ncbi:9606">human</span>
###xml 330 335 <span type="species:ncbi:4932">yeast</span>
###xml 497 502 <span type="species:ncbi:9606">human</span>
###xml 718 723 <span type="species:ncbi:9606">human</span>
###xml 993 998 <span type="species:ncbi:9606">human</span>
To further test the proposed hRAD18-HHR6B interaction, we performed an immunoprecipitation experiment. First, we tagged human RAD18 with the HA epitope (HA-hRAD18) and HHR6B with 6xHis (His-HHR6B) at their N-termini using yeast expression vectors. Then, the tagged human RAD18 and HHR6B were expressed individually or together in yeast cells, which was confirmed by western blot analysis using antibodies specific to the HA or the 6xHis tag (Fig. 4, lanes 1-3). Cell-free extracts containing both human RAD18 and HHR6B were subsequently prepared for in vitro immunoprecipitation. As shown in Figure 4 (lane 5), the monoclonal antibody against the HA tag precipitated HA-hRAD18 from the cell extract, as expected. With human RAD18 precipitation, the HA antibody additionally co-precipitated the His-tagged HHR6B (Fig. 4, lane 5). Without HA-hRAD18 in the cell extract, His-HHR6B was not detected following immuno-precipitation with the HA antibody (Fig. 4, lane 4). These results indicate that human RAD18 and HHR6B form a protein complex when co-expressed.
###end p 40
###begin p 41
###xml 256 257 256 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd425f5">5</xref>
###xml 523 524 523 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd425f5">5</xref>
###xml 662 663 662 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd425f5">5</xref>
###xml 163 168 <span type="species:ncbi:4932">yeast</span>
###xml 385 390 <span type="species:ncbi:9606">human</span>
###xml 563 568 <span type="species:ncbi:9606">human</span>
###xml 702 707 <span type="species:ncbi:9606">human</span>
The immunoprecipitation experiment was extended to test the proposed hRAD18-HHR6A interaction. HA-hRAD18 and the His-tagged HHR6A (His-HHR6A) were co-expressed in yeast and cell-free extracts were then prepared for immuno-precipitation. As shown in Figure 5 (lane 2), HA-hRAD18 protein was precipitated by the anti-HA monoclonal antibody from extracts containing HA-hRAD18 as the only human protein. Without HA-hRAD18 in the cell extract, His-HHR6A was not detected following immunoprecipitation with the HA antibody (Fig. 5, lane 3). However, in the presence of human RAD18, the HA antibody precipitated both HA-RAD18 and His-HHR6A from the cell extracts (Fig. 5, lane 4). These results indicate that human RAD18 and HHR6A form a protein complex when co-expressed.
###end p 41
###begin title 42
Stable protein complexes of hRAD18-HHR6A and hRAD18-HHR6B
###end title 42
###begin p 43
###xml 436 437 436 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd425f6">6</xref>
###xml 760 761 760 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd425f6">6</xref>
###xml 918 919 918 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd425f6">6</xref>
###xml 999 1000 999 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd425f6">6</xref>
###xml 19 24 <span type="species:ncbi:9606">human</span>
###xml 150 155 <span type="species:ncbi:4932">yeast</span>
###xml 198 203 <span type="species:ncbi:9606">human</span>
###xml 371 376 <span type="species:ncbi:9606">Human</span>
###xml 929 934 <span type="species:ncbi:9606">human</span>
###xml 1171 1176 <span type="species:ncbi:9606">Human</span>
###xml 1237 1242 <span type="species:ncbi:9606">human</span>
###xml 1692 1697 <span type="species:ncbi:9606">human</span>
To examine whether human RAD18 interactions with HHR6A and HHR6B result in stable protein complexes that can be isolated and studied, we fractionated yeast cell extracts containing the co-expressed human proteins by liquid chromatography. Cell-free extracts containing hRAD18 and HHR6B were sequentially fractionated on Ni-Sepharose, FPLC Mono S and FPLC Mono Q columns. Human RAD18 was co-purified with HHR6B to near homogeneity (Fig. 6A). Cell-free extracts containing hRAD18 and HHR6A were then sequentially fractionated on Ni-Sepharose and FPLC Mono Q columns. During purification we noticed that HHR6A was poorly stained by silver. As a result, the HHR6A protein band was barely detectable in the most pure Mono Q fraction following silver staining (Fig. 6B). The presence of the His-tagged HHR6A in this fraction, however, was clearly revealed by western blot analysis using the specific anti-His antibody (Fig. 6C). Thus, human RAD18 was also co-purified with HHR6A to near homogeneity (Fig. 6B and C). To provide further evidence that the purified hRAD18 and HHR6A were in a complex, we loaded this Mono Q fraction onto a FPLC Superdex 200 gel filtration column. Human RAD18 and HHR6A were identified by western blotting. Again, human RAD18 was co-purified with HHR6A and eluted at a position corresponding to 86-105 kDa. In contrast, pure HHR6A alone eluted at a position corresponding to approximately14 kDa from this gel filtration column under identical chromatographic conditions. Due to the small size of HHR6A and the possibility of non-globular hRAD18 and/or HHR6A, we were unable to estimate a stoichiometry between these two proteins in the complex. These results show that human RAD18 forms a stable protein complex with HHR6A and another stable protein complex with HHR6B.
###end p 43
###begin title 44
DISCUSSION
###end title 44
###begin p 45
###xml 279 280 279 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c8">8</xref>
###xml 466 491 466 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Schizosaccharomyces pombe</italic>
###xml 506 511 506 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pombe</italic>
###xml 540 559 540 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Emericella nidulans</italic>
###xml 568 570 568 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c34">34</xref>
###xml 573 590 573 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Neurospora crassa</italic>
###xml 600 602 600 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c35">35</xref>
###xml 628 634 628 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et&#160;al.</italic>
###xml 35 40 <span type="species:ncbi:9606">human</span>
###xml 146 151 <span type="species:ncbi:4932">yeast</span>
###xml 184 189 <span type="species:ncbi:9606">human</span>
###xml 266 271 <span type="species:ncbi:4932">yeast</span>
###xml 304 309 <span type="species:ncbi:9606">human</span>
###xml 392 397 <span type="species:ncbi:9606">human</span>
###xml 466 491 <span type="species:ncbi:4896">Schizosaccharomyces pombe</span>
###xml 540 559 <span type="species:ncbi:162425">Emericella nidulans</span>
###xml 573 590 <span type="species:ncbi:5141">Neurospora crassa</span>
###xml 608 613 <span type="species:ncbi:10090">mouse</span>
###xml 915 920 <span type="species:ncbi:4932">yeast</span>
###xml 992 997 <span type="species:ncbi:4932">yeast</span>
We have identified and sequenced a human EST clone coding for full-length RAD18. In addition to sequence homology, several structural features of yeast Rad18 are also conserved in the human protein. However, the Walker type A nucleotide binding motif (GKS) found in yeast Rad18 (8) is not present in the human protein. As a result, we were unable to detect an ATPase activity of the purified human RAD18-HHR6B protein complex. RAD18 homologs have been identified in Schizosaccharomyces pombe (SPBC1734.06, pombe genome sequencing project), Emericella nidulans (uvsH) (34), Neurospora crassa (uvs-2) (35) and mouse (Van der Laan et al., GenBank Accession no. AF205278). We examined protein sequences of these RAD18 homologs and found that none of them contains the GKS Walker type A nucleotide binding motif. Thus, this nucleotide binding motif and weak ATPase activity are most likely unique features restricted to yeast Rad18 protein. This raised the possibility that the ATPase activity of yeast Rad18 may not be important to its lesion bypass function.
###end p 45
###begin p 46
###xml 127 131 127 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rad6</italic>
###xml 363 365 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c11">11</xref>
###xml 685 690 685 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD18</italic>
###xml 809 810 809 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd425f2">2</xref>
###xml 20 25 <span type="species:ncbi:4932">yeast</span>
###xml 121 126 <span type="species:ncbi:4932">yeast</span>
###xml 374 379 <span type="species:ncbi:4932">yeast</span>
###xml 417 423 <span type="species:ncbi:9606">humans</span>
###xml 533 539 <span type="species:ncbi:9606">humans</span>
###xml 707 712 <span type="species:ncbi:9606">human</span>
Genetic analyses in yeast have indicated the importance of lesion bypass in responding to DNA damage. As demonstrated by yeast rad6 mutants, complete loss of this lesion bypass function results in extreme sensitivity of cells to many DNA damaging agents, such as UV radiation. The effect on cell survival is as dramatic as the loss of nucleotide excision repair (11). Since yeast Rad6 and Rad18 counterparts exist in humans, we strongly believe that lesion bypass mechanisms dependent on RAD18, HHR6A and/or HHR6B are operational in humans. Consistent with the notion that lesion bypass is also a fundamental response to DNA damage in mammals, we observed ubiquitous expression of the RAD18 gene in various human tissues. Different mRNA levels were apparent in some tissue samples as revealed by RT-PCR (Fig. 2). However, due to the commercial nature of these samples, we were unable to rigorously control the mRNA preparations. This limitation prevented us from conducting a more quantitative comparison of the hRAD18 expression levels in different tissues.
###end p 46
###begin p 47
###xml 201 202 201 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c5">5</xref>
###xml 590 591 590 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c1">1</xref>
###xml 592 593 592 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c2">2</xref>
###xml 3 8 <span type="species:ncbi:4932">yeast</span>
###xml 256 262 <span type="species:ncbi:9606">humans</span>
###xml 329 334 <span type="species:ncbi:9606">human</span>
###xml 353 358 <span type="species:ncbi:9606">human</span>
###xml 583 588 <span type="species:ncbi:4932">yeast</span>
In yeast, complex formation between Rad18 and Rad6 is thought to be important during lesion bypass, as mutations that abolish such an interaction lead to a severe cellular sensitivity to UV radiation (5). This feature is likely of functional importance in humans as well. Supporting this notion, we observed interactions between human RAD18 and the two human homologs of Rad6, HHR6A and HHR6B. The inter-actions result in the formation of stable protein complexes, hRAD18-HHR6A and hRAD18-HHR6B. Since Rad18 and Rad6 are required for both error-free and error-prone lesion bypass in yeast (1,2), it is likely that hRAD18-HHR6A and hRAD18-HHR6B may also participate in both modes of lesion bypass. At present, however, it is not known how these two complexes participate in different lesion bypass mechanisms.
###end p 47
###begin p 48
###xml 179 181 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c26">26</xref>
###xml 182 184 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c27">27</xref>
###xml 277 279 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd425c36">36</xref>
###xml 535 539 530 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">REV3</italic>
###xml 544 548 539 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">REV7</italic>
###xml 1082 1087 1072 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD18</italic>
###xml 39 44 <span type="species:ncbi:9606">human</span>
###xml 433 438 <span type="species:ncbi:9606">human</span>
###xml 462 467 <span type="species:ncbi:4932">yeast</span>
###xml 695 700 <span type="species:ncbi:9606">human</span>
###xml 820 825 <span type="species:ncbi:9606">human</span>
###xml 869 874 <span type="species:ncbi:4932">yeast</span>
###xml 1076 1081 <span type="species:ncbi:9606">human</span>
###xml 1250 1256 <span type="species:ncbi:9606">humans</span>
The importance of DNA lesion bypass in human physiology is underscored by the recent discovery that XPV disease is caused by inactivation of the lesion bypass DNA polymerase eta (26,27). Clinically, XPV is characterized by photosensitivity and a predisposition to skin cancer (36). Since damage-induced mutagenesis is an important factor in carcinogenesis, the REV3 mutagenesis pathway is also expected to play an import-ant role in human health. Our results in yeast demonstrate that high levels of DNA polymerase zeta encoded by the REV3 and REV7 genes lead to enhanced mutagenesis following UV radiation (D.K.Rajpal, X.Wu and Z.Wang, submitted for publication). Thus, mutations that activate human DNA polymerase zeta are expected to stimulate damage-induced mutagenesis and may consequently lead to a higher risk of human cancers. Based on our understanding of the yeast model system, it is predicted that hRAD18, HHR6A and HHR6B likely play important roles at an early step in the REV3 mutagenesis pathway and the polymerase eta lesion bypass mechanism. Isolation of the human RAD18 gene and purification of the hRAD18-HHR6A and hRAD18-HHR6B protein complexes should facilitate future studies on both error-free and error-prone lesion bypass in humans.
###end p 48
###begin title 49
Figures and Tables
###end title 49
###begin p 50
###xml 43 48 <span type="species:ncbi:4932">yeast</span>
###xml 52 58 <span type="species:ncbi:9606">humans</span>
###xml 64 69 <span type="species:ncbi:9606">human</span>
###xml 98 103 <span type="species:ncbi:4932">yeast</span>
###xml 339 344 <span type="species:ncbi:4932">yeast</span>
###xml 459 464 <span type="species:ncbi:9606">human</span>
 Conserved sequence features of RAD18 from yeast to humans. The human RAD18 (hRAD18, top) and its yeast counterpart (yRAD18, bottom) were aligned. Identical amino acids are indicated by two dots and similar amino acids are indicated by a single dot. The two zinc finger motifs are shown in red and the putative nucleotide binding motif in yeast Rad18 is shown in blue. A positively charged segment and a negatively charged segment in the C-terminal region of human RAD18 are highlighted in green and purple, respectively.
###end p 50
###begin p 51
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD18</italic>
###xml 102 103 102 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 283 288 283 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD18</italic>
###xml 41 46 <span type="species:ncbi:9606">human</span>
###xml 120 125 <span type="species:ncbi:9606">human</span>
###xml 277 282 <span type="species:ncbi:9606">human</span>
 Expression of the RAD18 gene in various human tissues. First strand cDNA was synthesized from poly(A)+ mRNA of various human tissues as indicated and normalized against the constitutive gene glyceraldehyde-3-phosphate dehydrogenase. A 433 bp DNA fragment corresponding to the human RAD18 cDNA was amplified by 35 cycles of PCR. DNA products were separated by electrophoresis on a 1% agarose gel and visualized by ethidium bromide staining. Size markers in bp are shown on the right.
###end p 51
###begin p 52
###xml 147 151 147 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAL4</italic>
###xml 179 183 179 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAL4</italic>
###xml 297 298 297 298 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 314 315 314 315 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 330 331 330 331 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 346 347 346 347 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 364 365 364 365 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E</bold>
###xml 381 382 381 382 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
###xml 398 399 398 399 <bold xmlns:xlink="http://www.w3.org/1999/xlink">G</bold>
###xml 429 430 429 430 <bold xmlns:xlink="http://www.w3.org/1999/xlink">H</bold>
###xml 460 461 460 461 <bold xmlns:xlink="http://www.w3.org/1999/xlink">I</bold>
###xml 491 492 491 492 <bold xmlns:xlink="http://www.w3.org/1999/xlink">J</bold>
###xml 22 27 <span type="species:ncbi:9606">human</span>
###xml 71 76 <span type="species:ncbi:4932">yeast</span>
###xml 217 222 <span type="species:ncbi:4932">Yeast</span>
###xml 695 700 <span type="species:ncbi:4932">yeast</span>
 Interactions between human RAD18 and HHR6A or HHR6B determined by the yeast two-hybrid assay. The two-hybrid vectors pAS2 and pACT2 contained the GAL4 DNA binding domain and the GAL4 activation domain, respectively. Yeast Y190 cells were transformed with one plasmid or two plasmids as follows: (A) pAS2-hRAD18; (B) pAS2-HHR6A; (C) pAS2-HHR6B; (D) pACT2-hRAD18; (E) pACT2-HHR6A; (F) pACT2-HHR6B; (G) pAS2-hRAD18 + pACT2-HHR6A; (H) pAS2-hRAD18 + pACT2-HHR6B; (I) pAS2-HHR6A + pACT2-hRAD18; (J) pAS2-HHR6B + pACT2-hRAD18. The expression of the two-hybrid target gene, beta-galactosidase, was monitored by filter assays using X-Gal as the enzyme substrate. Expression of beta-galactosidase turned yeast colonies blue in the presence of X-Gal, indicating physical interactions between the two proteins tested.
###end p 52
###begin p 53
###xml 27 32 <span type="species:ncbi:9606">human</span>
###xml 51 56 <span type="species:ncbi:9606">Human</span>
###xml 178 183 <span type="species:ncbi:4932">yeast</span>
###xml 191 196 <span type="species:ncbi:4932">Yeast</span>
 Co-immunoprecipitation of human RAD18 with HHR6B. Human RAD18 and HHR6B were tagged at their N-termini with HA (HA-hRAD18) and 6xHis (His-HHR6B), respectively, and expressed in yeast cells. Yeast cell-free extracts (40 microg) containing HA-hRAD18 (lane 1), His-HHR6B (lane 2) or both (lane 3) were detected by western blot analysis for the presence of these proteins. Extracts (1 mg) containing His-HHR6B (lane 4) or both His-HHR6B and HA-hRAD18 (lane 5) were precipitated with a monoclonal anti-HA antibody as described in Materials and Methods. Protein pellets (anti-HA IP, +) were analyzed by western blot. During western blot analyses, His-HHR6B protein bands on the nitrocellulose membrane were detected first by a monoclonal anti-His antibody. Then, the same membrane was probed again with the anti-HA antibody to detect HA-hRAD18 protein bands. Protein markers are indicated on the left.
###end p 53
###begin p 54
###xml 27 32 <span type="species:ncbi:9606">human</span>
###xml 51 56 <span type="species:ncbi:9606">Human</span>
###xml 178 183 <span type="species:ncbi:4932">yeast</span>
 Co-immunoprecipitation of human RAD18 with HHR6A. Human RAD18 and HHR6A were tagged at their N-termini with HA (HA-hRAD18) and 6xHis (His-HHR6A), respectively, and expressed in yeast cells. Extracts (1.5 mg) containing HA-hRAD18 (lane 2), His-HHR6A (lane 3) or both His-HHR6A and HA-hRAD18 (lane 4) were precipitated with a monoclonal anti-HA antibody as described in Materials and Methods. Protein pellets were analyzed by western blot. Lane 1 is the immunoprecipitation control without any cell extracts. During western blot analyses, His-HHR6A protein bands on the nitrocellulose membrane were detected first by a monoclonal anti-His antibody. Then, the same membrane was probed again with the anti-HA antibody to detect HA-hRAD18 protein bands. Protein markers are indicated on the left.
###end p 54
###begin p 55
###xml 60 61 60 61 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 516 517 512 513 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 846 847 838 839 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 141 146 <span type="species:ncbi:4932">yeast</span>
###xml 597 602 <span type="species:ncbi:4932">yeast</span>
 Purified hRAD18-HHR6A and hRAD18-HHR6B protein complexes. (A) HHR6B and hRAD18 tagged with 6xHis and HA, respectively, were co-expressed in yeast cells (W303-1B) and purified through Ni-Sepharose, FPLC Mono S and FPLC Mono Q columns. A sample (10 microl) from the most pure Mono Q fraction was separated by electrophoresis on a 15% SDS-polyacrylamide gel and visualized by silver staining of the gel. The identities of HHR6B and hRAD18 on the gel (indicated by arrowheads) were confirmed by western blot analysis. (B) HHR6A and hRAD18 tagged with 6xHis and HA, respectively, were co-expressed in yeast cells (FF18739) and purified through Ni-Sepharose and FPLC Mono Q columns. A sample (10 microl) from the most pure Mono Q fraction was separated by electrophoresis on a 15% SDS-polyacrylamide gel and visualized by silver staining of the gel. (C) The same Mono Q sample (10 microl) as in (B) was analyzed by western blot using both anti-HA and anti-His monoclonal antibodies. Protein markers are indicated on the sides.
###end p 55
###begin title 56
ACKNOWLEDGEMENTS
###end title 56
###begin p 57
###xml 60 65 <span type="species:ncbi:4932">yeast</span>
###xml 151 156 <span type="species:ncbi:4932">yeast</span>
###xml 330 337 <span type="species:ncbi:4097">Tobacco</span>
We thank Errol Friedberg and I. Fabre for providing us with yeast strains Y190 and FF18739, respectively. We thank Deepak Rajpal for assistance in the yeast two-hybrid assays. We thank Elena Braithwaite, Elizabeth Lin and Deepak Rajpal for critical review of this manuscript. These studies were supported by a THRI grant from the Tobacco and Health Research Institute of the University of Kentucky and a New Investigator Award in Toxicology from the Burroughs Wellcome Fund.
###end p 57
###begin title 58
REFERENCES
###end title 58

